Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) today announced that it has submitted a Phase II protocol for the clinical study of Archexin® as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).
The Phase II study will assess the safety and efficacy of Archexin when used in combination with both carboplatin and paclitaxel as a second-line therapy in subjects who are platinum-sensitive following their first relapse. The study will be conducted at multiple centers in the United States, and subjects will be randomized to receive either carboplatin/paclitaxel or carboplatin/paclitaxel/Archexin. Various measures of clinical benefit will be assessed.
Ovarian cancer is the fifth most common cancer among women, and it causes more deaths than any other type of female reproductive cancer.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.